Tumor abnormality-oriented nanomedicine design
Anticancer nanomedicines have been proven effective in mitigating the side effects of
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …
chemotherapeutic drugs. However, challenges remain in augmenting their therapeutic …
Cholangiocarcinoma—evolving concepts and therapeutic strategies
SI Ilyas, SA Khan, CL Hallemeier, RK Kelley… - Nature reviews Clinical …, 2018 - nature.com
Cholangiocarcinoma is a disease entity comprising diverse epithelial tumours with features
of cholangiocyte differentiation: cholangiocarcinomas are categorized according to …
of cholangiocyte differentiation: cholangiocarcinomas are categorized according to …
MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage
The methylthioadenosine phosphorylase (MTAP) gene is located adjacent to the cyclin-
dependent kinase inhibitor 2A (CDKN2A) tumor-suppressor gene and is co-deleted with …
dependent kinase inhibitor 2A (CDKN2A) tumor-suppressor gene and is co-deleted with …
CC-90009, a novel cereblon E3 ligase modulator, targets acute myeloid leukemia blasts and leukemia stem cells
C Surka, L Jin, N Mbong, CC Lu, IS Jang… - Blood, The Journal …, 2021 - ashpublications.org
A number of clinically validated drugs have been developed by repurposing the CUL4-
DDB1-CRBN-RBX1 (CRL4CRBN) E3 ubiquitin ligase complex with molecular glue …
DDB1-CRBN-RBX1 (CRL4CRBN) E3 ubiquitin ligase complex with molecular glue …
Oncometabolites in renal cancer
C Yong, GD Stewart, C Frezza - Nature Reviews Nephrology, 2020 - nature.com
The study of cancer metabolism has evolved vastly beyond the remit of tumour proliferation
and survival with the identification of the role of 'oncometabolites' in tumorigenesis. Simply …
and survival with the identification of the role of 'oncometabolites' in tumorigenesis. Simply …
Dysregulated lipid synthesis by oncogenic IDH1 mutation is a targetable synthetic lethal vulnerability
D Thomas, M Wu, Y Nakauchi, M Zheng… - Cancer discovery, 2023 - AACR
Abstract Isocitrate dehydrogenase 1 and 2 (IDH) are mutated in multiple cancers and drive
production of (R)-2-hydroxyglutarate (2HG). We identified a lipid synthesis enzyme [acetyl …
production of (R)-2-hydroxyglutarate (2HG). We identified a lipid synthesis enzyme [acetyl …
Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic …
B Ma, H Meng, Y Tian, Y Wang, T Song, T Zhang, Q Wu… - BMC cancer, 2020 - Springer
Abstract Background Isocitrate dehydrogenase 1/2 (IDH1/2), BAP1, ARID1A and PBRM1
have been reported as the most frequent mutant genes in intrahepatic cholangiocarcinoma …
have been reported as the most frequent mutant genes in intrahepatic cholangiocarcinoma …
Biochemical and epigenetic insights into L-2-hydroxyglutarate, a potential therapeutic target in renal cancer
Abstract Purpose: Elevation of L-2-hydroxylgutarate (L-2-HG) in renal cell carcinoma (RCC)
is due in part to reduced expression of L-2-HG dehydrogenase (L2HGDH). However, the …
is due in part to reduced expression of L-2-HG dehydrogenase (L2HGDH). However, the …
Non‐genetic heterogeneity, altered cell fate and differentiation therapy
Altered capacity for self‐renewal and differentiation is a hallmark of cancer, and many
tumors are composed of cells with a developmentally immature phenotype. Among the …
tumors are composed of cells with a developmentally immature phenotype. Among the …
The time has come for targeted therapies for AML: lights and shadows
A Fiorentini, D Capelli, F Saraceni, D Menotti… - Oncology and …, 2020 - Springer
Acute myeloid leukemia (AML) is a complex disease characterized by genetic and clinical
heterogeneity and high mortality. After 40 years during which the standard of care for …
heterogeneity and high mortality. After 40 years during which the standard of care for …